Nathan Sim, John T Moon, Hanzhou Li, Nicholas Lima, Zachary Bercu, Janice Newsome
{"title":"获得TACE和TARE与美国地区和城市:一项大型回顾性医疗索赔数据库研究。","authors":"Nathan Sim, John T Moon, Hanzhou Li, Nicholas Lima, Zachary Bercu, Janice Newsome","doi":"10.1159/000546514","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Access to highly specialized interventional oncology procedures such as transarterial chemoembolization (TACE) and radioembolization (TARE) may be limited in nonmetropolitan areas of the USA. This study aimed to evaluate whether disparities in access to TACE and TARE exists in these regions.</p><p><strong>Methods: </strong>This study characterizes the distribution of these procedures across regions by metropolitan status through utilization of a large commercial healthcare claims database (Truven Merative Marketscan). Patients with a diagnosis of primary hepatocellular carcinoma (n = 41,280) were categorized into those who received TACE (n = 1,780) or TARE (n = 1,179). Chi-squared tests of association were utilized to analyze regional data.</p><p><strong>Results: </strong>Statistical analyses showed significant differences between most regional comparisons with most patients receiving these procedures originating from metropolitan areas overall.</p><p><strong>Conclusion: </strong>Though limited to TACE and TARE, this study reveals a disparate distribution of TACE and TARE utilization across regions with preference toward metropolitan over nonmetropolitan areas, which may represent a barrier for access to care for nonmetropolitan patients, though this remains to be studied.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-5"},"PeriodicalIF":1.8000,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Access to Transarterial Chemoembolization and Transarterial Radioembolization with Respect to Region and Urbanity in the USA: A Large Retrospective Healthcare Claims Database Study.\",\"authors\":\"Nathan Sim, John T Moon, Hanzhou Li, Nicholas Lima, Zachary Bercu, Janice Newsome\",\"doi\":\"10.1159/000546514\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Access to highly specialized interventional oncology procedures such as transarterial chemoembolization (TACE) and radioembolization (TARE) may be limited in nonmetropolitan areas of the USA. This study aimed to evaluate whether disparities in access to TACE and TARE exists in these regions.</p><p><strong>Methods: </strong>This study characterizes the distribution of these procedures across regions by metropolitan status through utilization of a large commercial healthcare claims database (Truven Merative Marketscan). Patients with a diagnosis of primary hepatocellular carcinoma (n = 41,280) were categorized into those who received TACE (n = 1,780) or TARE (n = 1,179). Chi-squared tests of association were utilized to analyze regional data.</p><p><strong>Results: </strong>Statistical analyses showed significant differences between most regional comparisons with most patients receiving these procedures originating from metropolitan areas overall.</p><p><strong>Conclusion: </strong>Though limited to TACE and TARE, this study reveals a disparate distribution of TACE and TARE utilization across regions with preference toward metropolitan over nonmetropolitan areas, which may represent a barrier for access to care for nonmetropolitan patients, though this remains to be studied.</p>\",\"PeriodicalId\":19497,\"journal\":{\"name\":\"Oncology\",\"volume\":\" \",\"pages\":\"1-5\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-05-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000546514\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000546514","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
Access to Transarterial Chemoembolization and Transarterial Radioembolization with Respect to Region and Urbanity in the USA: A Large Retrospective Healthcare Claims Database Study.
Introduction: Access to highly specialized interventional oncology procedures such as transarterial chemoembolization (TACE) and radioembolization (TARE) may be limited in nonmetropolitan areas of the USA. This study aimed to evaluate whether disparities in access to TACE and TARE exists in these regions.
Methods: This study characterizes the distribution of these procedures across regions by metropolitan status through utilization of a large commercial healthcare claims database (Truven Merative Marketscan). Patients with a diagnosis of primary hepatocellular carcinoma (n = 41,280) were categorized into those who received TACE (n = 1,780) or TARE (n = 1,179). Chi-squared tests of association were utilized to analyze regional data.
Results: Statistical analyses showed significant differences between most regional comparisons with most patients receiving these procedures originating from metropolitan areas overall.
Conclusion: Though limited to TACE and TARE, this study reveals a disparate distribution of TACE and TARE utilization across regions with preference toward metropolitan over nonmetropolitan areas, which may represent a barrier for access to care for nonmetropolitan patients, though this remains to be studied.
期刊介绍:
Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.